Genmab A/S (GNMSF)
USD 203.33
(0.0%)
USD 203.33
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.35 Billion DKK | -20.18% |
| 2022 | 5.45 Billion DKK | 84.38% |
| 2021 | 2.95 Billion DKK | -37.85% |
| 2020 | 4.75 Billion DKK | 119.67% |
| 2019 | 2.16 Billion DKK | 47.15% |
| 2018 | 1.47 Billion DKK | 33.33% |
| 2017 | 1.1 Billion DKK | -7.0% |
| 2016 | 1.18 Billion DKK | 55.48% |
| 2015 | 763.51 Million DKK | 153.41% |
| 2014 | 301.29 Million DKK | 168.15% |
| 2013 | 112.36 Million DKK | 123.07% |
| 2012 | -487.11 Million DKK | 18.32% |
| 2011 | -596.36 Million DKK | -85.52% |
| 2010 | -321.45 Million DKK | 68.2% |
| 2009 | -1.01 Billion DKK | -4.73% |
| 2008 | -965.08 Million DKK | -151.74% |
| 2007 | -383.36 Million DKK | 12.52% |
| 2006 | -438.23 Million DKK | -11.34% |
| 2005 | -393.59 Million DKK | 5.21% |
| 2004 | -415.21 Million DKK | -26.93% |
| 2003 | -327.11 Million DKK | 31.76% |
| 2002 | -479.32 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.4 Billion DKK | 6.26% |
| 2024 Q1 | 1.32 Billion DKK | 107.03% |
| 2023 Q3 | 2.12 Billion DKK | 56.89% |
| 2023 Q1 | 210 Million DKK | -64.04% |
| 2023 FY | 4.35 Billion DKK | -20.18% |
| 2023 Q2 | 1.35 Billion DKK | 546.19% |
| 2023 Q4 | 640 Million DKK | -69.94% |
| 2022 FY | 5.45 Billion DKK | 84.38% |
| 2022 Q2 | 1.89 Billion DKK | 306.67% |
| 2022 Q1 | 465 Million DKK | -35.06% |
| 2022 Q3 | 2.58 Billion DKK | 36.54% |
| 2022 Q4 | 584 Million DKK | -77.38% |
| 2021 FY | 2.95 Billion DKK | -37.85% |
| 2021 Q4 | 716 Million DKK | -19.55% |
| 2021 Q3 | 890 Million DKK | 190.85% |
| 2021 Q2 | 306 Million DKK | -72.08% |
| 2021 Q1 | 1.09 Billion DKK | 88.64% |
| 2020 Q3 | 530 Million DKK | -84.31% |
| 2020 FY | 4.75 Billion DKK | 119.67% |
| 2020 Q4 | 581 Million DKK | 9.62% |
| 2020 Q2 | 3.37 Billion DKK | 1155.76% |
| 2020 Q1 | 269 Million DKK | -81.72% |
| 2019 Q3 | 537 Million DKK | 531.76% |
| 2019 Q2 | 85 Million DKK | 18.06% |
| 2019 Q1 | 72 Million DKK | -91.37% |
| 2019 Q4 | 1.47 Billion DKK | 174.09% |
| 2019 FY | 2.16 Billion DKK | 47.15% |
| 2018 Q2 | 260.52 Million DKK | 31.2% |
| 2018 Q1 | 198.57 Million DKK | -74.73% |
| 2018 FY | 1.47 Billion DKK | 33.33% |
| 2018 Q4 | 833.86 Million DKK | 365.39% |
| 2018 Q3 | 179.17 Million DKK | -31.23% |
| 2017 FY | 1.1 Billion DKK | -7.0% |
| 2017 Q4 | 785.86 Million DKK | 13933.27% |
| 2017 Q2 | 307.26 Million DKK | 1808.6% |
| 2017 Q3 | -5.68 Million DKK | -101.85% |
| 2017 Q1 | 16.09 Million DKK | -98.09% |
| 2016 Q3 | 188.95 Million DKK | 12.32% |
| 2016 FY | 1.18 Billion DKK | 55.48% |
| 2016 Q4 | 841.41 Million DKK | 345.29% |
| 2016 Q1 | -11.52 Million DKK | -102.96% |
| 2016 Q2 | 168.23 Million DKK | 1559.7% |
| 2015 Q1 | 217.29 Million DKK | 214.81% |
| 2015 Q3 | 140.26 Million DKK | 750.67% |
| 2015 Q2 | 16.48 Million DKK | -92.41% |
| 2015 Q4 | 389.46 Million DKK | 177.66% |
| 2015 FY | 763.51 Million DKK | 153.41% |
| 2014 Q3 | 159.92 Million DKK | 711.56% |
| 2014 FY | 301.29 Million DKK | 168.15% |
| 2014 Q4 | 69.02 Million DKK | -56.84% |
| 2014 Q2 | -26.15 Million DKK | -126.55% |
| 2014 Q1 | 98.5 Million DKK | 64.53% |
| 2013 Q3 | 5.34 Million DKK | 121.08% |
| 2013 FY | 112.36 Million DKK | 123.07% |
| 2013 Q2 | -25.34 Million DKK | -134.96% |
| 2013 Q1 | 72.49 Million DKK | 120.15% |
| 2013 Q4 | 59.86 Million DKK | 1020.49% |
| 2012 Q1 | -69.47 Million DKK | -58.6% |
| 2012 Q4 | -359.79 Million DKK | -545.15% |
| 2012 FY | -487.11 Million DKK | 18.32% |
| 2012 Q2 | -2.07 Million DKK | 97.01% |
| 2012 Q3 | -55.77 Million DKK | -2587.71% |
| 2011 Q1 | -111.22 Million DKK | -32.55% |
| 2011 Q3 | -360.77 Million DKK | -347.77% |
| 2011 Q2 | -80.57 Million DKK | 27.56% |
| 2011 FY | -596.36 Million DKK | -85.52% |
| 2011 Q4 | -43.8 Million DKK | 87.86% |
| 2010 Q4 | -83.9 Million DKK | -354.85% |
| 2010 Q2 | -88.69 Million DKK | 31.99% |
| 2010 Q1 | -130.4 Million DKK | 78.54% |
| 2010 FY | -321.45 Million DKK | 68.2% |
| 2010 Q3 | -18.44 Million DKK | 79.2% |
| 2009 Q1 | -199.15 Million DKK | 0.0% |
| 2009 FY | -1.01 Billion DKK | -4.73% |
| 2009 Q3 | -89.54 Million DKK | 21.76% |
| 2009 Q4 | -607.6 Million DKK | -578.54% |
| 2009 Q2 | -114.44 Million DKK | 42.53% |
| 2008 FY | -965.08 Million DKK | -151.74% |
| 2007 FY | -383.36 Million DKK | 12.52% |
| 2006 FY | -438.23 Million DKK | -11.34% |
| 2005 FY | -393.59 Million DKK | 5.21% |
| 2004 FY | -415.21 Million DKK | -26.93% |
| 2003 FY | -327.11 Million DKK | 31.76% |
| 2002 FY | -479.32 Million DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 252031.309% |
| CSL Limited | 2.64 Billion USD | -64.724% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 5905.531% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 66278.932% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 1591895.232% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -8114.576% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -6581.721% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 239151.528% |
| Mesoblast Limited | -87.95 Million USD | 5047.929% |
| Marizyme, Inc. | -65.34 Million USD | 6759.84% |
| Genus plc | 7.9 Million USD | -54988.608% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 40056.881% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 117397.184% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 49308.503% |
| ContraFect Corporation | -65.15 Million USD | 6779.662% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 89169.666% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | -36.48 Million USD | 12027.963% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 54097.168% |
| MultiCell Technologies, Inc. | -380.07 USD | 1145052327.221% |
| Accustem Sciences Inc. | -3.74 Million USD | 116264.262% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 8519.098% |
| EV Biologics, Inc. | -1.26 Million USD | 343552.232% |
| Q BioMed Inc. | -2.05 Million USD | 212176.158% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 116681.838% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 182890.325% |
| Biomind Labs Inc. | -1.21 Million USD | 358490.176% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 55167.048% |
| Skye Bioscience, Inc. | -37.64 Million USD | 11660.699% |
| SQZ Biotechnologies Company | -79.46 Million USD | 5576.694% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 29059929.06% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 62424.248% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 150563.595% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 27520.317% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 688264.426% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | -10.54 Million USD | 41359.006% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 200670.187% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 74911.943% |
| GB Sciences, Inc. | -1.36 Million USD | 319705.898% |
| Alpha Cognition Inc. | -13.77 Million USD | 31699.048% |
| argenx SE | -295.05 Million USD | 1574.989% |
| HST Global, Inc. | -146.21 Thousand USD | 2976640.592% |
| Halberd Corporation | -79.67 Thousand USD | 5462221.592% |
| Enzolytics Inc. | -2.17 Million USD | 200023.559% |
| Resverlogix Corp. | -3.61 Million USD | 120654.017% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 137324.904% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 7052.188% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 7386.682% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -4440716.327% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 140407.076% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -62748.45% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 223365.473% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 109639.584% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 143913.809% |
| AVAX Technologies, Inc. | -6.41 Million USD | 67955.299% |
| ONE Bio Corp. | 8.67 Million USD | -50057.827% |
| Zenith Capital Corp. | -10.59 Million USD | 41172.103% |
| Genscript Biotech Corporation | -95.47 Million USD | 4658.166% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 18724822.485% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 105070.265% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 7200556.779% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 217144.908% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 248109.569% |
| Agentix Corp. | -1.37 Million USD | 316790.814% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | -3.3 Million USD | 131683.801% |
| Helix BioMedix, Inc. | -1.05 Million USD | 412198.968% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 114056.533% |
| BioStem Technologies, Inc. | -8.48 Million USD | 51402.702% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 986123.033% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 325987.298% |
| LadRx Corporation | 400.44 Thousand USD | -1086696.373% |
| Cell Source, Inc. | -5.32 Million USD | 81885.879% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 1047565.696% |
| Regen BioPharma, Inc. | 1.02 Million USD | -425104.297% |
| Regen BioPharma, Inc. | 1.02 Million USD | -425104.297% |
| NovAccess Global Inc. | -4.76 Million USD | 91352.45% |
| Affymax, Inc. | -14.42 Million USD | 30271.936% |
| Itoco Inc. | -1.86 Million USD | 232952.415% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 98062.087% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 260854.943% |
| CytoDyn Inc. | -49.84 Million USD | 8831.767% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 5506660.551% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 1907809.302% |
| Qrons Inc. | -789.34 Thousand USD | 551441.805% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 462326.867% |
| SYBLEU INC | -180.3 Thousand USD | 2413801.304% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | 208560.867% |
| Rebus Holdings, Inc. | -1.02 Million USD | 426766.667% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 269951.811% |
| Mobile Lads Corp. | -2.26 Million USD | 192386.28% |
| International Stem Cell Corporation | -131 Thousand USD | 3322237.405% |
| Bioxytran, Inc. | -4.28 Million USD | 101782.195% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 8018967.925% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 172099.018% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 9153.087% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 205965.658% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 557414.951% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 137473.737% |
| Neutra Corp. | -233.46 Thousand USD | 1864190.977% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 21547.933% |
| PureTech Health plc | -65.69 Million USD | 6724.351% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 20564.075% |
| IXICO plc | -1.17 Million USD | 369539.728% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 43940.032% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 7717.981% |
| CSL Limited | 2.64 Billion USD | -64.724% |
| Cellectis S.A. | -103.17 Million USD | 4318.123% |